Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by ...

Delpacibart etedesiran led mostly to mild to moderate adverse events in a phase I/II trial of myotonic dystrophy type 1, but two serious events occurred. The antibody-oligonucleotide conjugate reduced ...

Figure 1. (a) Schematic diagram of the synthesis of TA-TMT, TA/DTTA-2-TMT, and DTTA-TMT; (b) PXRD patterns of TA-TMT, (c) TA/DTTA-2-TMT, and (d) DTTA-TMT. Inspired by the "barrel effect", the team ...

Department of Molecular and Cellular Biosciences, Centro de Investigaciones Biológicas Margarita Salas, CSIC. C/Ramiro de Maeztu, 9., 28040 Madrid, Spain Department of Molecular and Cellular ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, ...

Conjugated hyperbilirubinemia occurs when bilirubin, a by-product of red blood cells, builds up in the blood. This can indicate several underlying causes, such as hepatitis, cirrhosis, or biliary ...

VANCOUVER, BC / ACCESS Newswire / April 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a commercial stage biopharmaceutical company focused on ...

Expanded recommendations from the Advisory Committee on Immunization Practices on the use of pneumococcal conjugate vaccines may improve disease prevention among adults aged between 50 and 64 years.

Researchers have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results, the approach combined the benefits of ...